Tags : Signed


Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013

Shots: Y-Biologics to receive ~$2M up front and eligible to receive ~$85M as development, regulatory, & commercialization milestones along with royalties on sales in the territory 3D Medicines will get an exclusive right to develop, manufacture, and commercialize YBL-013 in China with the expansion of collaboration in the US and other regions Both the companies […]Read More


AbbVie Terminates Tau and ASN Agreement with Voyager Signed in

Shots: Voyager retains full rights to the vectorization technology and novel vectorized Abs emerges from the collaboration and has the right to pursue vectorized Ab programs targeting tau and alpha-synuclein alone or in collaboration with another partner As per collaboration agreements, Voyager has received an upfront payment to perform research and preclinical development of vectorized […]Read More


Sierra Oncology Amends its Asset Purchase Agreement with Gilead for

Shots: As per the amended agreement, Gilead will reduce the royalty rates of Momelotinib & eliminates milestone payments in exchange for becoming a stockholder in Sierra, following the closing of Sierra’s qualified financing. In Aug’2018, Sierra acquired Gilead’s Momelotinib for $3M up front, $195M milestones and royalties on sales Additionally, Sierra and Gilead Sciences would […]Read More


AbbVie Exercises its Option to License Agreement for BioArctic’s Alpha-Synuclein

Shots: BioArctic to get $755M as total deal value (with upfront previously paid) and $50M milestone payments in addition to royalties on sales In 2016, AbbVie and BioArctic ($80M upfront) entered into a global collaboration to develop & commercialize BioArctic’s Alpha-Synuclein Ab Platform to treat Parkinson Disease BAN0805, a leading BioArctic’s Alpha-Synuclein Ab indicated for […]Read More